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Enhanced anticoagulation and/or even bleeding are often observed when patients on
long-term warfarin (WAR) therapy consumed Danshen, a well-known medicinal herb in
traditional Chinese medicine (TCM). This study demonstrates that altered WAR metabolism,
arising from its interaction with the active components in Danshen, played a significant role in
this curative effect. Mass spectrometric techniques including ESI-ITMS (electrospray ionization
ion-trap mass spectrometry) and ESI-TOF (time-of-flight)-MS have been developed for the
study of such drug–herb interactions. The experimental approach involved a detailed analysis
and comparison of WAR metabolites in vivo from blood or urine of rats that had been orally
administrated with WAR, either singly or together with the representative bioactive compo-
nent of Danshen–lipid soluble TIIA (Tanshinon IIA), and a study of the interaction of human
serum albumin (HSA), WAR, and water-soluble sodium tanshinone IIA sulfonate (STS) in
vitro. Results demonstrate that TIIA accelerates the metabolic rate of WAR, whereas STS
displaces WAR from the WAR–HSA complex, resulting in an increase of free WAR concen-
tration in blood. It is suggested that the elevated level and enhanced metabolism of WAR is
responsible for the over-anticoagulation effect observed. (J Am Soc Mass Spectrom 2008, 19,
1568–1575) © 2008 Published by Elsevier Inc. on behalf of American Society for Mass
SpectrometryThe root of Salvia miltiorrhiza is known in China asDanshen, which is a widely used traditionalChinese medicine (TCM) and officially listed in
the Chinese Pharmacopeia. It is mainly used for the
treatment of coronary heart diseases, particularly an-
gina pectoris and myocardial infarction [1]. Tanshinone
IIA (TIIA) is one of the representative bioactive compo-
nents in the lipid-soluble fraction of Danshen [2]. Many
biological studies have been carried out on this rela-
tively abundant component. A water-soluble derivative
of tanshinone, sodium tanshinone IIA sulfonate (STS),
has in fact been tested clinically in coronary heart
disease patients with positive results on causing coro-
nary vasodilatation and inhibiting coronary artery
spasm [3].
Many medicinal herbs and pharmaceutical drugs are
therapeutic at one dose and toxic at another. Interac-
tions between herbs and drugs may increase or de-
crease the pharmacological or toxicological effects of
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doi:10.1016/j.jasms.2008.06.005either component, and the subject is the focus of this
study. Warfarin (WAR), with its known effect of inhib-
iting vitamin K-dependent coagulation factors, is a
common anticoagulant agent that has been introduced
into clinical medicine for more than 40 yr [4, 5]. It has
been reported that anticoagulation could be enhanced,
sometimes even to the extent of bleeding, when WAR is
dosed together with Danshen. Danshen cannot react
with WAR directly under physiological conditions,
suggesting the lack of true “pharmacy interaction”
between Danshen and WAR. However, some type of
pharmacokinetic interaction between the two may have
played an important role in Danshen’s well-documented
effects on blood concentration, clearance, and apparent
volume of distribution of WAR [6–11].
The serum albumin, as one of the most abundant
carrier proteins, can bind to a number of relatively
insoluble endogenous compounds such as unesterified
fatty acids, bilirubin and bile acids. It also binds a wide
variation of drugs and xenobiotics to facilitate their
transport throughout the circulatory system [12–18].
WAR, a highly protein-bound drug, binds to the protein
through site 1, which is a preformed binding pocket
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albumin (HSA) [19, 20]. Danshen is also strongly protein-
bound and albumin is the major serum protein that
binds to Danshen [21]. As the major component of
Danshen, TIIA has been reported to bind to HSA, which
can be detected by the red shift of the maximum
absorption wavelength of TIIA and an enhancement of
the absorbance [22]. So it is proposed that Danshen may
change the plasma protein binding of WAR by displac-
ing WAR from its binding sites, resulting in over-
anticoagulant because of the increased blood concentra-
tion of WAR [11]. Like most herbal plants, the bioactive
components in Danshen are extremely complex. A
study of the interactions involved between WAR and
the entire Danshen extract is therefore an ineffective
way to sort out the mechanistic pathways between the
two. In this study, instead, Danshen IIA was chosen as
a representative bioactive species of Danshen, and its
interaction with WAR was investigated to gain better
insight on the mechanisms involved in protein–drug
interactions at a molecular level.
There are several analytical techniques that have
been used for the analysis of noncovalently bound
complex. Xie et al. [23] used a spectroscopic method to
investigate the interaction between 2,3-dihydro-4=,5,7-
trihydroxyflavone and HSA. Kreutz et al. [24] presented
a novel concept for the identification of RNA binders by
19F nuclear magnetic resonance (NMR) spectroscopy.
X-ray was also used by Kaiser et al. [25] to analyze the
complex eukaryotic 20S proteasome with the natural
inhibitor TMC-95A. The chief disadvantage of spectro-
scopic methods is that they cannot provide a direct
readout of the stoichiometry of the binding partners in
protein–ligand complexes. Although NMR and X-ray
crystallography can yield high-resolution structures of
biomolecules and complexes from the solution phase
and solid phase, respectively, both of these techniques
require relatively large quantities of materials and are
time consuming. Moreover, NMR is limited to mole-
cules with molecular weight not exceeding 40 kDa;
furthermore, not all proteins are easy to crystallize for
X-ray crystallography detection [26]. Electrospray ion-
ization mass spectrometry (ESI-MS) has recently
emerged as an attractive alternative [27–31]. Although
unable to provide direct structural data as NMR and
X-ray crystallography, ESI-MS does provide important
stoichiometry information of the complex formed be-
tween two binding partners. Experimentally, the tech-
nique also enjoys the merits of high analytical speed
and small sample requirement. ESI is a soft ionization
technique that allows for the direct analysis of proteins
in their biologically active form in the solution. Because
of its high sensitivity and moderate resolution at very
high m/z (e.g., above m/z 6000), the time-of-flight (TOF)
analyzer coupled with ESI ionization (ESI-TOF-MS)
provides an ideal system for the detection of macromol-
ecules and large noncovalent complexes [32, 33], and
has been widely used for probing noncovalent protein–
ligand interactions [34–37].In this study, ESI-ion trap-MS (ESI-ITMS) was used
for the detection of metabolites of WAR in vivo to study
the effect of TIIA on the metabolism of WAR. Then
ESI-TOF-MS was applied to monitor the interactions
among Danshen, WAR, and HSA. This approach rep-
resents the first such attempt in the literature. The
mechanism of interaction between Danshen and WAR
and how this interaction affects the noncovalent bind-
ing of WAR with HSA are also the main topics of
interest.
Experimental
Material and Reagents
Warfarin (WAR), tanshinone IIA (TIIA), and sodium
tanshinone IIA sulfonate (STS) were purchased from
the National Institute for the Control of Pharmaceutical
and Biological Products (NICPBP, Beijing, China). Hu-
man serum albumin (HSA, fraction V) was purchased
from Sigma Chemical Co. (St. Louis, MO, USA).
Ammonium acetate was from Fluka (Zwijndrecht,
The Netherlands). HPLC-grade methanol and acetoni-
trile were purchased from Tedia (Fairfield, OH, USA).
Purified deionized water (18.2 M) prepared by a
Milli-Q Ultrapure water system (Millipore, Bedford,
MA, USA) was used for all buffers. Male Sprague–
Dawley (S.D.) rats were purchased from Laboratory
Animal Services Centre, the Chinese University of
Hong Kong. Other reagents used were of analytical
grade purity.
Preparation of the Metabolites of TIIA and WAR
In Vivo
Male S.D. rats with weight between 200 and 220 g were
under the process of oral administration as described
previously [38]. Three rats were sorted to a group. WAR
(4 mg) and a mixture of WAR (4 mg) and TIIA (4 mg)
were each orally administrated to the rats of different
groups. Urine was collected up to 12 h after oral
administration. The samples were kept at20 °C before
pretreatment. Then the rats were decapitated and the
blood was collected with antithrombin heparin. Based
on the method described by Qian [39], blood was first
centrifuged at 8200  g for 20 min to collect the plasma.
Then 300 L of plasma sample was measured and put
into a 1.5 mL polystyrene tube with 1 mL methanol,
mixed well, and then centrifuged at 8200  g for 20 min
to precipitate out the protein from the supernatant
containing WAR and its metabolites. The supernatant
was transferred into another tube and dried under a
stream of nitrogen. The residue was reconstituted with
50 L of methanol and then centrifuged at 8200  g for
20 min. A volume of 5 L of the supernatant was
analyzed by liquid chromatography (LC)/MS. Urine
samples were also pretreated following the method
previously described [38] before LC/MS analysis.
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of HSA and Ligands
The HSA stock solution was prepared by dissolving 25
mg HSA in 1 mL 20 mM NH4Ac buffer (pH 7.4). Stock
solutions of WAR and STS were respectively prepared
in methanol and NH4Ac buffer to a concentration of 1
mg/mL. For the reaction of ligand binding to HSA, the
HSA stock solution was added to 20 mM NH4Ac buffer
(pH 7.4) to make a final concentration of 50 M. Ligand
was then added to the solution followed by thorough
mixing. The solution was incubated at 37 °C, and the
HSA–WAR complex was produced from the two after a
certain incubation time. The dynamic process of the
binding reaction was monitored at different concentra-
tion ratios of HSA to ligand and at different incubation
times. The STS was titrated and the mass variations of
HSA–ligand complexes were observed to study the
effect of TIIA on WAR binding HSA.
Mass Spectrometry
A Bruker Esquire 4000 ion trap mass spectrometer
(Bruker-Fransen, Bremen, Germany) was used for the
ESI-MS analysis of the metabolites of WAR extracted
from the bioassay. The operational parameter settings
were as follows: pressure of nebulizer gas, 50 psi; ion
spray voltage, 4500 V; flow rate, 12 L/min; temperature
of the drying gas, 350 °C. Negativ e-ion mode was used
in MS analysis with the mass range scanned from m/z
100–600. A collision energy of 0.35 V was used to
acquire the fragment ion spectra of the metabolites.
Coupled with liquid chromatography, metabolites
could be separated from the complex biomatrix before
MS analysis. An HP 1100 liquid chromatograph
(Hewlett-Packard, Wilmington, DE, USA), equipped
with a Phenomenex C18 reverse-phase column (150 
2.0 mm, 5 m), was used for separation. NH4Ac buffers
(5 mM) containing 0.1% (vol/vol) acetic acid (A) and
methanol (B) were used as the HPLC mobile phase. A
gradient elution was set as follows: 5% B was increased
to 50% from 0 to 30 min, then held for 10 min. The flow
rate of the mobile phase was set at 0.4 mL/min.
Protein–ligand complexes were analyzed with an
Agilent G1969A TOF mass spectrometer equipped with
an ESI source (Agilent Technologies, Palo Alto, CA,
USA) under positive-ion mode. Sample solution was
directly infused with mobile phase containing 20 mM
NH4Ac buffer (pH 5.0) at a flow rate of 20 L/min. A
mixed standard for tuning solution was used for tuning
and mass calibration. This instrument was under opti-
mum conditions with a resolution of about 18,000 at m/z
2721 and mass error  3 ppm. Relevant parameters
were adjusted to obtain optimum resolution for analy-
sis of the protein–ligand complex. The temperature,
flow rate of the drying gas, and nebulizer pressure were
set at 270 °C, 7 L/min, and 15 psi, respectively. The
potential of capillary and skimmer were set at 2700 and
70 V. Enhancing the potential of fragmentor and octu-pole radio frequency voltage (Oct RFV) increases the
sensitivity for detecting ions with high m/z. So the
fragmentor was set at 400V and Oct RFV was set at
300V. The scanning mass range of the mass spectrom-
eter was from m/z 600 to 6000.
Results and Discussion
Metabolites of TIIA and WAR In Vivo
WAR was metabolized in the liver by the cytochrome
P450 system [40]. Like other extrinsic matters, WAR
also undergoes two metabolic phases in vivo. The
principal metabolism of WAR in phase I was catalyti-
cally converted to a series of monohydroxylated metab-
olites. Some minor metabolites such as dehydro-
warfarin and warfarin alcohols were also formed. In
phase II, the hydroxylated warfarin metabolites were
mainly glucuronidated and sulfated before being ex-
creted into urine (80%) and feces (20%) [5, 41, 42].
When TIIA was metabolized together with WAR in
vivo, no new additional metabolites other than those
observed in pure WAR systems as described earlier
were found in urine or blood. The observation suggests
the absence of metabolic reactions or pharmacy inter-
actions between the two species.
No WAR was detected in the urine sample collected
12 h after oral administration with WAR (Figure 1aI).
However, WAR was found in the urine if the rat was
orally administered WAR together with TIIA (Figure
1aII). Besides WAR itself, warfarin alcohol (Figure 1bII),
dehydro-warfarin (Figure 1cII), several monohydroxy-
lated metabolites of WAR (Figure 1dII), glucuronida-
tion of hydroxy-warfarin (Figure 1eII) and sulfated
conjugate of hydroxy-warfarin (Figure 1fII) were also
detected in the urine excreted from rats dosed with the
mixture containing WAR and TIIA. However, except
for a very low concentration of the sulfated conjugate of
hydroxy-warfarin (Figure 1fI), few other metabolites
were observed in the urine sample from rats dosed with
WAR alone (Figure 1b, c, d, eI). Negative-ion MS/MS
spectra of WAR and its metabolites are shown in Figure
2. All metabolites have a structure similar to that of
WAR, but individual metabolites differ in characteristic
substituents, thus producing their own characteristic
MS/MS spectra. Figure 2b shows the MS/MS spectrum
of warfarin-alcohol. The fragment of –CH2CH(OH)CH3
is lost, indicating the characteristic structure of warfa-
rin-alcohol. Dehydro-warfarin loses a particular frag-
ment of O¢C¢CH2 in the MS/MS process (Figure 2c).
Compared with the MS/MS spectrum of WAR (Figure
2a), those of hydroxy-warfarin show the loss of one
more H2O, indicating the presence of an additional
hydroxy group in this metabolite. The MS/MS spectra
of the two phase II metabolites, glucuronidation of
hydroxy-warfarin and the sulfated conjugate of hy-
droxy-warfarin, are shown in Figure 2e and f, respec-
tively. The two metabolites behave similarly by first
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and sulfate, respectively, followed by a loss of
CH3COCH3, which is a characteristic fragment in the
MS/MS spectrum of WAR (Figure 2a). The results
acquired from the blood samples were similar. Metab-
Figure 1. Extracted ion chromatograms of warfarin and its
metabolites in urine samples under the in vivo metabolism of
warfarin single (I) and with tanshinone IIA (II).olites of WAR were clearly detectable in blood from ratsdosed with a mixture of WAR and IIA, but few metab-
olites of WAR were detected if rats were dosed by WAR
alone (data not shown). These results show that dosing
of the mixture increased the concentration of free WAR
in blood. Such an increase could have accelerated the
rate of metabolism of WAR, resulting in an increase of
the varieties and concentrations of metabolites in urine
in a time period of 12 h. In general, the drugs, once
entering the organism, will bind first with serum albu-
min. They are then transported through blood circula-
tion to the receptors and other tissues. At the same time,
a dynamic balance exists among the free drug mole-
cules and the bound drugs. The bound drugs would
gradually release the drugs in free forms. The free
drugs are then metabolized by related enzymes in liver
and other organs [43] and result in curative or toxic
effects after reactions at the receptor sites. So the mech-
anism upon the addition of TIIA that accelerated the
rate of metabolism of WAR is considered as the replace-
ment of WAR by TIIA at the WAR–HSA binding site.
The process increases the concentration of free drugs in
blood and, in turn, the metabolic reaction rate of WAR.
Noncovalent Interaction between HSA and WAR
Similar to other proteins, a typical ESI mass spectrum of
the HSAmolecules consists of clusters of ion peaks with
consecutive multiple charges that originate from the
attachment of different number of protons. Figure 3
shows the two clusters of ion peaks in the mass spec-
trum of HSA under the conditions described earlier in
the experimental section. The cluster of ion peaks with
high charge states indicates the partially denaturized
HSA. Here the HSA molecules have an unfolded con-
figuration, thus making available more space and sites
on the molecules for proton binding. In the mass
spectrum of the other cluster of ion peaks, four charge
states ranging from 15 to 19 were observed, corre-
sponding to HSA in its native state [44, 45]. At this state,
the HSA can bind effectively with ligands to form
noncovalent complexes, and such complex formation
between WAR and HSA with different protein–ligand
ratios has been reported [46, 47].
To study the mechanistics of WAR–HSA interac-
tions, a series of mixtures of WAR and HSA with molar
ratios of 1:1, 2:1, 5:1, 10:1, and 20:1 WAR to HSA were
prepared in 20 mM ammonium acetate buffer (pH 7.4),
making a final HSA concentration of 50 M. After
thorough mixing, they were incubated in a 37 °C water
bath for 2 h. Figure 4a compares the molar ratio of the
HSA–WAR complex to HSA as quantified by their
relative MS intensity at different WAR/HSA ratios after
2 h of incubation. When WAR and HSA were incubated
with the ratios of 1:1 and 2:1, only small amounts of
complexes were observed. When the ratio was in-
creased to 5:1, the relative abundance of complex to
HSA increased noticeably. A further increase of the
WAR to HSA ratio beyond 5:1 resulted in little change
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tion times were studied at a constant WAR to HSA ratio
(5:1). The effect of incubation time on the formation of
the HSA–WAR complex is shown in Figure 4b. The
relative abundance of the complex relative to HSA
reached the maximum after 30 min incubation. In the
following 1.5 h, the relative abundance stayed at about
the same level. Based on the results, an incubation time
of 30 min and a ratio of WAR to HSA at 5:1 were chosen
as the optimum conditions for further experiments on
the noncovalent interaction of WAR and HSA in vitro
by direct ESI-TOF-MS study as described in the follow-
ing text.
Reactions among HSA, WAR, and STS
Figure 5a shows the MS spectrum of a reaction mixture
Figure 2. MS/MS spectra of the [M  H] i
negative-ion mode.at 1:5 M ratio of HSA to WAR. At the beginning ofincubation, only signals of free HSA were observed,
i.e., an intact HSA molecular ion with multiple charge
states between 15 and 19, corresponding to the
molecular weight of 66,429  2 Da. After 30 min
incubation at 37 °C, additional peaks corresponding
to complex formation between HSA and one WAR
ligand with a mass of 66,737  2 Da was observed
after deconvolution (Figure 5b). Since the molecular
weight of WAR is 308, the observed mass thus
corresponded to a stoichiometry of 1:1 M ratio for the
complex of HSA to WAR. Then STS with the same
concentration as that of WAR was added to the
incubation solution, and the interaction between STS
and complex HSA–WAR was also monitored at dif-
ferent times. Figure 5c–e shows the mass spectra and
mass variation of HSA and the complexes after
incubation for 0, 15, and 30 min, respectively. Besides
of warfarin and its metabolites in vivo underonsthe ion peaks of HSA, several additional peaks were
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sponded to HSA–ligand complexes with the same
charge states as that of native HSA. For the mass
variation of the complex, the relative abundance of
HSA–WAR decreased with the increase of a new
peak. The new peak with a mass of 66,802  2 Da
represented a mass increase of 373 Da over the parent
HSA, corresponding to the mass of STS (396 Da)
without a sodium atom. Because STS existed in the
form of tanshinone IIA sulfonate (TS) and Na ions in
water, TS will substitute STS to bind with HSA,
resulting in the formation of a complex of HSA–TS
with a molecular mass of 66,802  2 Da and a
stoichiometry of 1:1 HSA to TS. The result indicated
that the addition of STS indeed affected the noncova-
lent binding between HSA and WAR by competing
with WAR for the same binding site on HSA. As a
result, more bound WAR molecules were set free,
along with an increase of the amount of HSA–TS
complex at the expense of those of HSA–WAR.
Conclusions
An ESI-ITMS-based method was developed for the
study of WAR–Danshen interactions. Results demon-
strated that the active component of Danshen, TIIA,
affects the pharmacokinetics of WAR through an alter-
ation of its metabolism. Monitored by ESI-ITMS, WAR
and its metabolites were detected with high concentra-
tions in urine and blood collected from the rats orally
dosed by WAR together with TIIA. When WAR alone
was orally administrated to rats, a low level of WAR
and only a few of its metabolites were detected in urine
or blood.
An ESI-TOF-MS-based method was developed for
the study of noncovalent interactions of HSA and
Figure 3. ESI-mass spectrum of HSA with denatured and intact
forms.ligands. A complex of HSA–WAR with the stoichi-ometry of 1:1 was detected when WAR was incubated
together with HSA in vitro. STS, a water-soluble
derivative of TIIA having the same curative effect as
that of TIIA, was able to effectively reduce the
relative concentration of HSA–WAR complex while
enhancing the relative concentration of a different
complex, HSA–TS, indicating the ability of TS to
replace WAR from its binding site on the HSA–WAR
complex. These results explained the over-anticoag-
ulation phenomenon observed in patients treated by
WAR together with Danshen.
Overall, our results show that TIIA interacts phar-
macokinetically with WAR through affecting the con-
centration and metabolic pathways of WAR in blood.
The study also illustrates the effectiveness of ESI-MS
and TOF-MS methodologies in studying the pharma-
cological interactions between drugs and proteins.
Further experiments to understand the mechan-
istic basis of the curative effects of tanshinones and
how it interacts with the biological receptors are in
progress.
Figure 4. Variations of relative abundance of HSA–WAR com-
plexes formed in reaction mixtures containing different WAR to
HSA ratios (a) and under different encubation times (b).
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